DEF: Progyny Schedules 2026 Annual Meeting, Proposes Governance Changes

Progyny, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for May 21, 2026, to be held virtually, and has proposed amendments to its Certificate of Incorporation to eliminate certain supermajority voting requirements.

Summary

• Progyny, Inc. is holding its 2026 Annual Meeting of Stockholders virtually on May 21, 2026.
• The meeting agenda includes the election of three Class I directors, ratification of Ernst & Young LLP as the independent auditor for fiscal year 2026, and an advisory vote on executive compensation.
• Key proposals also involve amending the Certificate of Incorporation to eliminate certain supermajority voting requirements and to change the voting standard for business combinations with interested stockholders.
• The company is providing proxy materials electronically via the internet, with a record date of March 27, 2026.
• Detailed information on director nominees, executive compensation, and corporate governance is included in the proxy statement.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive, highlighting strong business performance and proactive engagement on executive compensation, while also noting the routine nature of the governance proposals.

Positives

• The company is holding a virtual annual meeting to increase accessibility and participation for stockholders globally.
• Proposed amendments to the Certificate of Incorporation aim to streamline corporate governance by eliminating supermajority voting requirements, potentially facilitating quicker decision-making.
• The company actively engaged with stockholders in 2025 to understand and address concerns regarding executive compensation, leading to significant program changes.
• Progyny highlights record revenue, Adjusted EBITDA, and operating cash flow in 2025 with double-digit year-over-year growth.
• A near 100% client retention rate has been maintained for the tenth consecutive year.
• New program launches in pregnancy, parent/child wellbeing, and menopause care have expanded coverage to millions of lives.
• Clinical outcomes for fertility and maternal health services remain superior to national averages.

Negatives

• The company experienced a significant drop in stockholder support for its say-on-pay proposal in 2024, with only 35.7% voting in favor, down from 97.6% in 2023, indicating potential dissatisfaction with executive compensation practices.
• The filing notes that Mr. Clapp, Ms. Cummings, and Ms. Scott had late Section 16(a) filings, indicating minor compliance issues.

Risks

• The staggered three-year terms for directors may delay or prevent a change in management or a change in control of Progyny.
• The company's executive compensation program is subject to ongoing review and potential adjustments based on market data and stockholder feedback, which could lead to changes in compensation structures.
• The proposed amendments to the Certificate of Incorporation, while intended to streamline governance, could alter the balance of power between management and stockholders regarding certain business combinations and director removal.
• The company's reliance on a specific peer group for compensation benchmarking may not always reflect the most accurate market comparisons, especially given M&A activity within the industry.

Future Outlook

The filing does not contain specific forward-looking financial guidance but focuses on upcoming corporate events and governance proposals. The company's business highlights for 2025 suggest a positive trajectory, with new program launches and expanded offerings expected to contribute to future growth.

Management Comments

• We believe that hosting a virtual meeting will increase stockholder attendance and participation because stockholders can participate from any location around the world, while saving the Company and investors time and money.
• Our board of directors has carefully considered its leadership structure and determined that Mr. Schlanger is best situated to serve as executive chairman given his deep knowledge of our business and strategy.
• The board of directors believes its approach to risk oversight ensures that the board of directors can choose many leadership structures while continuing to effectively oversee risk.
• We believe that our compensation programs and policies for the year ended December 31, 2025 were an effective incentive for the achievement of the Company's goals, aligned with stockholders interests, and are worthy of stockholder support.
• We believe that our compensation mix supports our objectives of motivating, rewarding, attracting, and retaining high caliber management deemed essential to ensuring our success and aligning executive compensation with our short- and long-term objectives, business strategy, and financial performance.

Industry Context

StockSavvy.ai notes that Progyny's focus on specialized benefits in fertility, family building, and women's health aligns with a growing trend in employer-provided benefits aimed at improving employee well-being and retention. The proposed governance changes, particularly the elimination of supermajority voting requirements, reflect a broader corporate governance trend towards simplifying decision-making processes.

Comparison to Industry Standards

• Progyny's client retention rate of nearly 100% for ten consecutive years significantly exceeds industry averages for benefits providers, indicating strong client satisfaction and value proposition.
• The company's clinical outcomes in fertility and maternal health services are reported as superior to national averages, suggesting best-in-class care delivery within the healthcare services sector.
• The executive compensation structure, with a significant portion in variable, at-risk compensation (annual bonuses and long-term equity), aligns with best practices for publicly traded companies in the healthcare and technology sectors, aiming to link pay to performance.
• The introduction of Performance Stock Units (PSUs) tied to revenue and Adjusted EBITDA in the long-term incentive program is a common and effective practice among peer companies to align executive interests with long-term shareholder value creation.

Corporate Governance

Related Party Transactions

• Progyny entered into a consulting agreement with Michael Sturmer, its former president, effective January 1, 2026, for an annual fee of $250,000. The agreement has an initial term until December 31, 2026, with automatic one-year renewals unless terminated. If Mr. Sturmer consults through June 30, 2026, his vested options will have an extended exercise period.

Stakeholder Impact

• Stockholders: Will vote on director elections, auditor ratification, executive compensation, and significant corporate governance changes. The proposed changes to voting requirements could impact their influence on certain corporate actions.
• Employees: The company's compensation philosophy aims to attract, motivate, and retain talent. New programs launched in 2025 and 2026 will impact employee benefits and access to care.
• Management: Executive compensation is detailed, with a focus on performance-based incentives and alignment with stockholder interests. Changes to compensation programs have been made in response to stockholder feedback.
• Directors: Nominees are presented for election, and compensation for non-employee directors is detailed, including cash retainers and equity awards.

Next Steps

• Stockholders are encouraged to vote their shares in advance of the Annual Meeting via internet, telephone, or mail.
• Stockholders can attend the virtual Annual Meeting online.
• Final voting results will be disclosed in a Form 8-K filing within four business days after the Annual Meeting.
• The company expects to publish an impact report on its website in 2026 regarding its approach to corporate responsibility.

Key Dates

Recommendation

The filing is a routine proxy statement for an annual meeting, detailing governance proposals and executive compensation. While the company reported strong financial performance in 2025, the proposals themselves are standard corporate actions and do not present new material information that would warrant a buy or sell recommendation at this time. A 'hold' recommendation is appropriate pending further strategic or financial updates.

Keywords

Progyny, Annual Meeting, Proxy Statement, Corporate Governance, Executive Compensation, Director Election, Auditor Ratification, Certificate of Incorporation Amendment, Supermajority Voting, Business Combinations, Stockholder Vote